Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phased avelumab combined with first-line chemotherapy for advanced small-cell lung cancer
2017-004784-12Phase 2Completed
- Sponsor
- HeCOG
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in small cell lung cancer (SCLC), sponsored by HeCOG. Primary endpoints: Progression-free survival rate at 1 year and Progression-free survival. Started Mar 2018; status: completed.
02
Drugs
avelumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2017-004784-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004784-12.